Stryker Corporation

New York Stock Exchange
Back to all articles
Slightly Bullish +25

Former Stryker Medical Division President Brad Saar Joins Sonablate Board to Support Growth of Non-Invasive Prostate Cancer Treatment

👤 Sonablate appointed Brad Saar, former Stryker Medical Division President, to its Board of Directors.

🏥 Saar brings over 30 years of global medical technology leadership experience from Stryker.

💰 During his tenure at Stryker, he oversaw a multibillion-dollar business with 15 acquisitions totaling $7.4 billion.

🚗 Sonablate's HIFU technology is FDA-cleared in the U.S. for non-invasive prostate tissue ablation without incisions.

🎯 The company's "precision sound medicine" platform aims to preserve patient function while treating disease with surgical-level precision.

📈 Saar expressed that prostate cancer treatment is reaching an inflection point where non-invasive approaches are gaining broader clinical consideration.

🗓️ Sonablate will participate in the ASCA + SAMBA 2026 Conference & Expo and AUA Annual Meeting both in May 2026.

🎤 At AUA2026, Sonablate will host educational sessions on real-world use of HIFU for prostate cancer and benign prostatic hyperplasia (BPH).

🌍 The company's FUSION Global Registry is ongoing to generate real-world evidence supporting the platform's validation and adoption.

🎉 A Women in Focal Therapy Leadership forum will convene during the AUA2026 meeting to advance education and collaboration.

🤝 CEO Richard Yang noted that Sonablate is well-positioned to scale globally with experienced leadership and growing clinical interest.

🌐 Sonablate's HIFU system has received regulatory approvals in more than 50 countries worldwide beyond the United States.

💡 The company focuses on expanding international adoption and increasing physician utilization of the focused ultrasound platform.

🧠 Saar's experience scaling global medtech platforms is expected to support advancing Sonablate’s platform to the next growth phase.

🔒 Both Stryker Medical Division and Sonablate prioritize treatments that aim to preserve quality of life for patients.

Bullish Signals
  • Sonablate announced the appointment of Brad Saar, former President of Stryker's Medical Division, to its Board of Directors to support growth.
  • Brad Saar brings more than 30 years of experience in global medical technology leadership and previously delivered sustained double-digit growth while leading 15 acquisitions totaling $7.4 billion at Stryker.
  • Sonablate's HIFU technology is FDA-cleared in the United States and has received regulatory approvals in more than 50 countries worldwide.
  • The company plans to participate in high-profile industry meetings including the ASCA + SAMBA 2026 Conference & Expo and the American Urological Association Annual Meeting (AUA2026) in May to increase physician adoption and awareness.
  • Sonablate will host educational sessions and discussions focused on real-world use of HIFU, patient selection, and its application in both prostate cancer and benign prostatic hyperplasia (BPH).
  • CEO Richard Yang stated that with experienced leadership and growing clinical interest, Sonablate is well positioned to scale globally and advance precision sound medicine as a foundational approach to treating prostate disease.
  • The company is convening clinical and industry stakeholders during AUA2026, including a Women in Focal Therapy Leadership forum focused on advancing education, collaboration, and leadership.
Risk Factors
  • The article highlights Brad Saar's previous experience with acquisitions at Stryker, totaling $7.4 billion across 15 deals, which may suggest Sonablate is likely to pursue a similar aggressive acquisition strategy that could dilute existing shareholders.
  • Sonablate relies on FDA clearance for only the United States market and has regulatory approvals in more than 50 countries worldwide, indicating potential dependency on international regulatory pathways that are often slower or more costly to navigate.
  • The announcement focuses entirely on Brad Saar joining the board, with no mention of Sonablate's current financial results, revenue growth, or profitability metrics, raising questions about the company's standalone performance without this high-profile appointment.
Full Analysis
Sonablate, a medical technology company specializing in high-intensity focused ultrasound (HIFU) for non-invasive prostate cancer treatment, announced the appointment of Brad Saar to its Board of Directors on April 30, 2026. Saar, formerly the President of Stryker’s Medical Division, brings over 30 years of global medical technology leadership experience to the company. During his tenure at Stryker, he oversaw a multibillion-dollar business that achieved sustained double-digit growth and completed 15 acquisitions totaling $7.4 billion while driving global manufacturing expansion. His expertise is expected to aid Sonablate in expanding international adoption, increasing physician utilization, and advancing its "precision sound medicine" platform, which uses targeted ultrasound energy to treat disease with surgical-level precision while preserving patient function. Sonablate's HIFU technology was FDA-cleared in the United States for prostate tissue ablation and is utilized as a non-invasive alternative to surgery and radiation by targeting specific prostate tissue without incisions. The company aims to increase adoption across the urology community through growing clinical engagement and physician education, particularly as interest shifts toward focal therapy and outpatient care models. Saar noted that prostate cancer treatment is reaching an inflection point where non-invasive approaches are moving beyond early adoption into broader clinical consideration, driven by a priority to preserve quality of life. As part of its ongoing growth strategy, Sonablate will participate in upcoming industry meetings this May, including the ASCA + SAMBA 2026 Conference & Expo and the American Urological Association Annual Meeting (AUA2026). At AUA2026, the company plans to host educational sessions on real-world HIFU use, patient selection, and the role of focal therapy in treating both prostate cancer and benign prostatic hyperplasia (BPH). These efforts are supported by initiatives such as the FUSION Global Registry, which aims to generate real-world evidence for validation and adoption. Sonablate CEO Richard Yang stated that with experienced leadership like Saar's and growing clinical interest, the company is well-positioned to scale globally and advance precision sound medicine as a foundational approach to treating prostate disease. Sonablate positions itself as a global leader in non-invasive, focused ultrasound technologies, with its Sonablate® HIFU system having received regulatory approvals in more than 50 countries worldwide. The addition of Saar to the board reflects the company's continued focus on supporting the evolution of prostate cancer treatment toward precise, non-invasive, and function-preserving approaches. This strategic move underscores Sonablate's commitment to positioning precision sound medicine at the forefront of the next generation of urologic care while continuing to build clinical engagement within the medical community.